FORMATION OF ETHINYLESTRADIOL IN POSTMENOPAUSAL WOMEN DURING CONTINUOUS TREATMENT WITH A COMBINATION OF ESTRADIOL, ESTRIOL AND NORETHISTERONE ACETATE

被引:32
作者
KLEHRBATHMANN, I
KUHL, H
机构
[1] UNIV FRANKFURT,DEPT OBSTET & GYNECOL,DIV GYNECOL ENDOCRINOL,D-60590 FRANKFURT,GERMANY
[2] GYNECOL PRACTICE,TRAUNSTEIN,GERMANY
关键词
NORETHISTERONE; AROMATIZATION; ETHINYLESTRADIOL; REPLACEMENT THERAPY;
D O I
10.1016/0378-5122(94)00894-D
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Previous studies indicated that during treatment of postmenopausal women with preparations containing norethisterone, a small proportion of the progestogen is aromatized into ethinylestradiol. We therefore investigated the serum concentrations of estradiol, ethinylestradiol and norethisterone in 25 patients of a gynecological practice who were continuously treated for climacteric complaints with a combination of 2 mg estradiol, 1 mg estriol and 1 mg norethisterone acetate for a time period between 4 months and 6 years. Blood sampling occurred between I and 20 h after intake of the last tablet. The mean serum concentration of estradiol was 138 +/- 50 (53-279) pg/ml, of ethinylestradiol 18.1 +/- 13.5 (0-44) pg/ml, and of norethisterone 5.1 +/- 3.5 (0.7-1 1.6) ng/ml. The serum concentrations of estradiol showed a broad maximum between 1 and 14 h, and those of norethisterone a steep rise to maximum within 1-4 h after intake followed by a subsequent decline. Contrary to this, the ethinylestradiol levels were not related to the time after application indicating that the aromatization of norethisterone mainly occurs in peripheral tissue. There was no correlation between age, body mass index or duration of treatment and the ethinylestradiol levels. It is concluded that in the presence of the high estradiol concentrations the low conversion rate of norethisterone into ethinylestradiol is probably without clinical significance.
引用
收藏
页码:245 / 250
页数:6
相关论文
共 22 条
[1]   PHARMACOKINETICS AND BIOTRANSFORMATION OF ORALLY-ADMINISTERED ESTRONE SULFATE AND ESTRADIOL VALERATE IN POSTMENOPAUSAL WOMEN [J].
AEDO, AR ;
LANDGREN, BM ;
DICZFALUSY, E .
MATURITAS, 1990, 12 (04) :333-343
[2]   EFFECT OF ORALLY-ADMINISTERED ESTROGENS ON CIRCULATING ESTROGEN PROFILES IN POST-MENOPAUSAL WOMEN [J].
AEDO, AR ;
SUNDEN, M ;
LANDGREN, BM ;
DICZFALUSY, E .
MATURITAS, 1989, 11 (02) :159-168
[3]  
Baird D T, 1969, Recent Prog Horm Res, V25, P611
[4]   EFFECTS OF AGING AND OBESITY ON AROMATASE-ACTIVITY OF HUMAN ADIPOSE-CELLS [J].
CLELAND, WH ;
MENDELSON, CR ;
SIMPSON, ER .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (01) :174-177
[5]   AROMATASE-ACTIVITY OF MEMBRANE-FRACTIONS OF HUMAN ADIPOSE-TISSUE STROMAL CELLS AND ADIPOCYTES [J].
CLELAND, WH ;
MENDELSON, CR ;
SIMPSON, ER .
ENDOCRINOLOGY, 1983, 113 (06) :2155-2160
[6]   TIME-DEPENDENT BIPHASIC RESPONSE OF AROMATASE TO DEXAMETHASONE IN CULTURED HUMAN-SKIN FIBROBLASTS [J].
FUJIMOTO, M ;
BERKOVITZ, GD ;
BROWN, TR ;
MIGEON, CJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1986, 63 (02) :468-474
[7]   INHIBITION OF ORAL-CONTRACEPTIVE STEROID METABOLIZING ENZYMES BY STEROIDS AND DRUGS [J].
GUENGERICH, FP .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (06) :2159-2163
[8]  
JASONNI M, 1984, MATURITAS, V5, P251, DOI 10.1016/0378-5122(84)90018-5
[9]   COMPARATIVE METABOLISM OF ESTRONE SULFATE AFTER ORAL AND INTRAVENOUS ADMINISTRATION IN POSTMENOPAUSAL WOMEN [J].
JASONNI, VM ;
NALDI, S ;
CIOTTI, P ;
BULLETTI, C ;
FLAMIGNI, C .
MATURITAS, 1987, 9 (03) :201-205
[10]   ORAL-CONTRACEPTIVES CONTAINING 20 OR 30 MU-G ETHINYLESTRADIOL AND 150 MU-G DESOGESTREL - PHARMACOKINETICS AND PHARMACODYNAMIC PARAMETERS [J].
JUNGHOFFMANN, C ;
FITZNER, M ;
KUHL, H .
HORMONE RESEARCH, 1991, 36 (5-6) :238-246